Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
BSTC's Cash to Debt is ranked higher than
100% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. BSTC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BSTC' s 10-Year Cash to Debt Range
Min: 0.06  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.97
BSTC's Equity to Asset is ranked higher than
97% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BSTC: 0.97 )
Ranked among companies with meaningful Equity to Asset only.
BSTC' s 10-Year Equity to Asset Range
Min: -5.34  Med: 0.80 Max: 0.98
Current: 0.97
-5.34
0.98
Interest Coverage No Debt
BSTC's Interest Coverage is ranked higher than
99% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BSTC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BSTC' s 10-Year Interest Coverage Range
Min: 80.45  Med: 10000.00 Max: 9999.99
Current: No Debt
80.45
9999.99
F-Score: 6
Z-Score: 255.32
M-Score: -1.48
WACC vs ROIC
5.51%
73.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 55.73
BSTC's Operating margin (%) is ranked higher than
97% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. BSTC: 55.73 )
Ranked among companies with meaningful Operating margin (%) only.
BSTC' s 10-Year Operating margin (%) Range
Min: -296.7  Med: -17.08 Max: 54.91
Current: 55.73
-296.7
54.91
Net-margin (%) 36.77
BSTC's Net-margin (%) is ranked higher than
93% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. BSTC: 36.77 )
Ranked among companies with meaningful Net-margin (%) only.
BSTC' s 10-Year Net-margin (%) Range
Min: -300.13  Med: 2.42 Max: 63.95
Current: 36.77
-300.13
63.95
ROE (%) 22.58
BSTC's ROE (%) is ranked higher than
92% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. BSTC: 22.58 )
Ranked among companies with meaningful ROE (%) only.
BSTC' s 10-Year ROE (%) Range
Min: -343.89  Med: 5.41 Max: 61.21
Current: 22.58
-343.89
61.21
ROA (%) 21.85
BSTC's ROA (%) is ranked higher than
96% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. BSTC: 21.85 )
Ranked among companies with meaningful ROA (%) only.
BSTC' s 10-Year ROA (%) Range
Min: -156.91  Med: 4.68 Max: 53.14
Current: 21.85
-156.91
53.14
ROC (Joel Greenblatt) (%) 290.52
BSTC's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. BSTC: 290.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BSTC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -406600  Med: -4.33 Max: 275.15
Current: 290.52
-406600
275.15
Revenue Growth (3Y)(%) 6.70
BSTC's Revenue Growth (3Y)(%) is ranked higher than
58% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. BSTC: 6.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BSTC' s 10-Year Revenue Growth (3Y)(%) Range
Min: -47  Med: 7.15 Max: 65.8
Current: 6.7
-47
65.8
EBITDA Growth (3Y)(%) 10.80
BSTC's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. BSTC: 10.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BSTC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 3.25 Max: 166.8
Current: 10.8
0
166.8
EPS Growth (3Y)(%) -11.40
BSTC's EPS Growth (3Y)(%) is ranked lower than
54% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. BSTC: -11.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BSTC' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.2  Med: 0.00 Max: 76.5
Current: -11.4
-44.2
76.5
» BSTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BSTC Guru Trades in Q2 2014

Jim Simons 67,009 sh (+349.72%)
Chuck Royce 100,000 sh (unchged)
» More
Q3 2014

BSTC Guru Trades in Q3 2014

Jim Simons 109,000 sh (+62.66%)
Chuck Royce 86,600 sh (-13.40%)
» More
Q4 2014

BSTC Guru Trades in Q4 2014

Jim Simons 145,101 sh (+33.12%)
Chuck Royce 48,600 sh (-43.88%)
» More
Q1 2015

BSTC Guru Trades in Q1 2015

Jim Simons 179,200 sh (+23.50%)
Chuck Royce 48,600 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BSTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 77.37
BSTC's P/E(ttm) is ranked lower than
70% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. BSTC: 77.37 )
Ranked among companies with meaningful P/E(ttm) only.
BSTC' s 10-Year P/E(ttm) Range
Min: 14.34  Med: 37.56 Max: 109.97
Current: 77.37
14.34
109.97
Forward P/E 51.02
BSTC's Forward P/E is ranked lower than
77% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. BSTC: 51.02 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 71.60
BSTC's PE(NRI) is ranked lower than
70% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. BSTC: 71.60 )
Ranked among companies with meaningful PE(NRI) only.
BSTC' s 10-Year PE(NRI) Range
Min: 15.05  Med: 43.39 Max: 108.5
Current: 71.6
15.05
108.5
P/B 13.44
BSTC's P/B is ranked lower than
83% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BSTC: 13.44 )
Ranked among companies with meaningful P/B only.
BSTC' s 10-Year P/B Range
Min: 4.65  Med: 8.31 Max: 525
Current: 13.44
4.65
525
P/S 28.94
BSTC's P/S is ranked lower than
69% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. BSTC: 28.94 )
Ranked among companies with meaningful P/S only.
BSTC' s 10-Year P/S Range
Min: 2.57  Med: 14.97 Max: 75
Current: 28.94
2.57
75
POCF 113.70
BSTC's POCF is ranked lower than
80% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. BSTC: 113.70 )
Ranked among companies with meaningful POCF only.
BSTC' s 10-Year POCF Range
Min: 1.05  Med: 41.44 Max: 3172
Current: 113.7
1.05
3172
EV-to-EBIT 45.48
BSTC's EV-to-EBIT is ranked lower than
56% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. BSTC: 45.48 )
Ranked among companies with meaningful EV-to-EBIT only.
BSTC' s 10-Year EV-to-EBIT Range
Min: -124.1  Med: 0.65 Max: 63.9
Current: 45.48
-124.1
63.9
Shiller P/E 146.37
BSTC's Shiller P/E is ranked lower than
77% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. BSTC: 146.37 )
Ranked among companies with meaningful Shiller P/E only.
BSTC' s 10-Year Shiller P/E Range
Min: 66.64  Med: 105.81 Max: 1000
Current: 146.37
66.64
1000
Current Ratio 31.82
BSTC's Current Ratio is ranked higher than
95% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. BSTC: 31.82 )
Ranked among companies with meaningful Current Ratio only.
BSTC' s 10-Year Current Ratio Range
Min: 0.43  Med: 5.79 Max: 37.48
Current: 31.82
0.43
37.48
Quick Ratio 31.82
BSTC's Quick Ratio is ranked higher than
95% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BSTC: 31.82 )
Ranked among companies with meaningful Quick Ratio only.
BSTC' s 10-Year Quick Ratio Range
Min: 0.41  Med: 5.09 Max: 37.48
Current: 31.82
0.41
37.48
Days Sales Outstanding 78.88
BSTC's Days Sales Outstanding is ranked lower than
62% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. BSTC: 78.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSTC' s 10-Year Days Sales Outstanding Range
Min: 5.36  Med: 81.81 Max: 299.91
Current: 78.88
5.36
299.91

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.39
BSTC's Price/Net Cash is ranked lower than
73% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. BSTC: 20.39 )
Ranked among companies with meaningful Price/Net Cash only.
BSTC' s 10-Year Price/Net Cash Range
Min: 2.84  Med: 12.57 Max: 65.22
Current: 20.39
2.84
65.22
Price/Net Current Asset Value 16.56
BSTC's Price/Net Current Asset Value is ranked lower than
72% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. BSTC: 16.56 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BSTC' s 10-Year Price/Net Current Asset Value Range
Min: 1.05  Med: 6.90 Max: 40.52
Current: 16.56
1.05
40.52
Price/Tangible Book 13.88
BSTC's Price/Tangible Book is ranked lower than
76% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. BSTC: 13.88 )
Ranked among companies with meaningful Price/Tangible Book only.
BSTC' s 10-Year Price/Tangible Book Range
Min: 0.59  Med: 2.89 Max: 425
Current: 13.88
0.59
425
Price/Projected FCF 18.42
BSTC's Price/Projected FCF is ranked lower than
78% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. BSTC: 18.42 )
Ranked among companies with meaningful Price/Projected FCF only.
BSTC' s 10-Year Price/Projected FCF Range
Min: 0.66  Med: 8.94 Max: 133
Current: 18.42
0.66
133
Price/Median PS Value 1.93
BSTC's Price/Median PS Value is ranked lower than
70% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. BSTC: 1.93 )
Ranked among companies with meaningful Price/Median PS Value only.
BSTC' s 10-Year Price/Median PS Value Range
Min: 0.04  Med: 0.38 Max: 4.07
Current: 1.93
0.04
4.07
Price/Graham Number 6.78
BSTC's Price/Graham Number is ranked lower than
73% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. BSTC: 6.78 )
Ranked among companies with meaningful Price/Graham Number only.
BSTC' s 10-Year Price/Graham Number Range
Min: 0.86  Med: 2.44 Max: 8.67
Current: 6.78
0.86
8.67
Earnings Yield (Greenblatt) (%) 2.23
BSTC's Earnings Yield (Greenblatt) (%) is ranked higher than
85% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BSTC: 2.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSTC' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.6  Med: 3.80 Max: 1259.6
Current: 2.23
1.6
1259.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
BioSpecifics Technologies Corp was incorporated in Delaware in 1990. It is a biopharmaceutical company engaged in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase for indications in development. Auxilium is currently selling XIAFLEX in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease. In December 2013, FDA approved Auxilium's supplemental Biologics License Application ('sBLA') for XIAFLEX for the treatment of Peyronie's disease. The Company and its licensees face competition from larger pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products. As a biopharmaceutical company, the Company is subject to a large body of legal and regulatory requirements.
» More Articles for BSTC

Headlines

Articles On GuruFocus.com
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 09 2010 
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-03-31 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-06-30 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-09-30 Jan 13 2009 
BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market Jan 06 2009 

More From Other Websites
The First Half of 2015 Was a Huge Win for Biotech Investors: Here Are the Top Picks of the Top Stock... Jul 30 2015
Edited Transcript of BSTC earnings conference call or presentation 12-May-15 1:00pm GMT Jul 20 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 20 2015
BioSpecifics Announces Approval of XIAFLEX® in Japan for the Treatment of Dupuytren's Contracture Jul 20 2015
BioSpecifics Announces Approval of XIAFLEX® in Japan for the Treatment of Dupuytren's Contracture Jul 20 2015
Coverage initiated on BioSpecifics Tech by MLV & Co Jul 16 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 19 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Jun 01 2015
BioSpecifics Technologies Corp. to Present at the Jefferies 2015 Healthcare Conference May 26 2015
BioSpecifics Technologies Corp. to Present at the Jefferies 2015 Healthcare Conference May 26 2015
BIOSPECIFICS TECHNOLOGIES CORP Financials May 20 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 20 2015
BioSpecifics Reports Presentation of First Ever Treatment Guidelines for Peyronie's Disease and... May 19 2015
BioSpecifics Reports Presentation of First Ever Treatment Guidelines for Peyronie's Disease and... May 19 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... May 18 2015
BioSpecifics posts 1Q profit May 11 2015
BioSpecifics posts 1Q profit May 11 2015
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 11 2015
BioSpecifics Technologies Corp. Reports First Quarter 2015 Financial Results May 11 2015
BioSpecifics Technologies Corp. Reports First Quarter 2015 Financial Results May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK